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ABSTRACT
 Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein 
highly expressed in several types of malignant tumors sometimes in association with 
increased tumor aggressiveness and poor clinical outcome. In the present study, 
1562 tumors were immunohistochemically analyzed for mesothelin expression using 
two different types of mouse monoclonal antibodies (5B2 and MN-1) to determine 
the clinical usefulness of mesothelin immunohistochemistry as well as to pinpoint 
potential targets for future anti-mesothelin therapy. Also, characterization of selected 
mesothelin-positive tumors was performed by immunohistochemistry and oncogene 
sequencing. Among the tumors analyzed, the highest frequencies of mesothelin-
positivity were detected in ovarian serous carcinoma (90% in 5B2 and 94% in 
MN-1). Both antibodies showed frequent positivity in pancreatic adenocarcinoma 
(71% using 5B2 and 87% using MN-1) and malignant pleural mesothelioma (75% 
using 5B2 and 78% using MN-1). In malignant mesothelioma, overall survival was 
significantly longer in the cohort of patients with diffuse membranous expression 
of mesothelin (P < 0.001). Both antibodies showed positive staining in thymic 
carcinoma (77% in 5B2 and 59% in MN-1), however, no expression was detected in 
thymoma. No correlation was detected between mesothelin expression and mismatch 
repair system deficient phenotype or gene mutation (BRAF and RAS) status in 
gastrointestinal adenocarcinomas. Mesothelin immunohistochemistry may assist the 
differential diagnosis of thymoma vs. thymic carcinoma as well as prognostication 
of mesothelioma patients. Our results demonstrate that patients with solid tumors 
expressing mesothelin could be targeted by anti-mesothelin therapies.
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INTRODUCTION
Mesothelin (MSLN) is a glycophosphatidylinositol 
(GPI)-linked cell surface protein normally expressed in 
mesothelial cells that line the pleura, peritoneum, and 
pericardium. The MSLN gene encodes a precursor protein 
of 71 kDa that is processed to a 31 kDa shed protein called 
MPF (megakaryocyte potentiating factor) and a 40 kDa 
membrane bound protein, mesothelin [1]. The biologic 
function of mesothelin is not well known, however, no 
detectable abnormalities were reported in growth and 
reproduction in a mesothelin deficient mouse model [2].
Mesothelin is reported to be highly expressed in several 
types of malignant tumors, such as malignant mesothelioma, 
ovarian cancer, pancreatic adenocarcinoma, and lung 
adenocarcinoma. In some cases, mesothelin expression has 
been associated with increased tumor aggressiveness and 
poor clinical outcome, however, its impact on the clinical 
outcome of malignant pleural mesothelioma patients has not 
been extensively evaluated [3–10]. In ovarian cancer, it has 
been shown that mesothelin binds to ovarian cancer antigen 
MUC16 (CA-125) and may contribute to dissemination into 
the abdominal cavity [11–13]. It has also been shown that 
mesothelin plays a pivotal role in tumor cell proliferation, 
invasion, and chemotherapy resistance through the activation 
of oncogenic signaling [14–16]. Although the mechanism(s) 
and/or tumor biological significances were unclear, high 
mesothelin expression was associated with KRAS gene 
mutation in lung adenocarcinoma [8, 9].
Anti-mesothelin immunotherapies for mesothelin-
expressing tumor include use of recombinant immunotoxin 
(SS1P), a high-affinity chimeric monoclonal antibody 
(MORAb-009), an anti-mesothelin antibody drug conjugate 
(BAY 94-9343), and adoptive T-cell immunotherapy using 
mesothelin-specific chimeric antigen receptors (CAR) 
[17]. Serum mesothelin levels have been found to correlate 
with mesothelioma responsiveness to anti-mesothelin 
therapies [18–21], however, it has not been shown whether 
immunohistochemistry can be used as a biomarker to 
predict clinical response to these drugs.
The aim of this study was to evaluate differential 
reactivity of different types of mouse monoclonal antibodies 
against mesothelin as well as MPF/precursor mesothelin for 
immunohistochemistry. It was also aimed to determine the 
clinical usefulness of mesothelin immunohistochemistry 
as well as to highlight tumor types for future mesothelin-
targeting therapy. Additional immunohistochemical and 
oncogene mutation analyses were performed to characterize 
the mesothelin-positive tumors. 
RESULTS
Comparison of two mesothelin and three MPF 
antibodies in 218 selected tumor tissues
 Immunohistochemical staining using two 
mesothelin (5B2, and MN-1) and three MPF (MPF25, 
MPF44, and MPF49) antibodies were performed in 
218 selected tumor tissues including ovarian serous 
carcinoma, pancreatic ductal carcinoma, thymic tumors, 
and malignant mesothelioma. Among them, MPF49 
antibody did not generate sufficient specific staining 
signals in a selection of mesothelin-positive tumors and 
was not studied further (data not shown). The results of 
immunohistochemistry using the two anti-mesothelin 
and two anti-MPF antibodies have been summarized 
in Table 1. The mesothelin antibodies (5B2 and MN-1) 
showed higher rates of positivity than MPF antibodies 
(MPF 25 and MPF 44) in all of the tumors analyzed. 
In malignant mesothelioma, mesothelin antibodies 
(5B2 and MN-1) showed membrane positivity, whereas 
MPF44 showed predominantly cytoplasmic staining. 
(Figure 1A and 1B) From this preliminary experiment, 
2 mesothelin antibodies, 5B2 and MN-1, were chosen 
for the study of normal tissues and a larger cohort of 
tumors because of their higher rates of positivity on 
initial screening.
Immunohistochemistry using 5B2 and MN-1 
antibodies in normal tissues and 1562 tumors
In normal tissues, both 5B2 and MN-1 antibodies 
showed limited mesothelin expression in the epithelium of 
fallopian tubes and seminal vesicles (Figure 2A and 2B). 
Also, Hassall’s corpuscles of the thymus and a subset of 
squamous epithelial cells of the tonsils showed mesothelin 
expression (Figure 2C and 2D).
Table 2 summarizes the results of immuno 
histochemistry for mesothelin using mouse monoclonal 
antibodies 5B2 and MN-1 in different types of tumors. 
Among them, high frequencies of mesothelin-positivity 
were detected in ovarian serous carcinoma (90%, median 
value of positive cells 90% in 5B2 and 94%, median value 
of positive cells 100% in MN-1) (Figure 3A and 3B). 
In other tumors with adenocarcinoma-like 
differentiation, both clones showed variable positivity on 
the cell membrane and cytoplasm of the neoplastic cells. 
MN-1 showed higher positive staining rate than 5B2 on the 
cell membrane in invasive ductal carcinoma of the pancreas 
(87% vs. 71%, Figure 4A and 4B), adenocarcinomas of the 
colorectum (61% vs. 48%) and stomach (49% vs. 38%).
Both antibodies showed similar positivity in 
malignant mesothelioma (75% in 5B2 and 78% in MN-1), 
uterine endometrioid adenocarcinoma (63% vs. 62%), 
intrahepatic cholangiocellular carcinoma (41% each), and 
invasive ductal carcinoma of the mammary gland (11% vs. 
12%). In malignant mesothelioma, 31% (45/143) and 40% 
(57/143) of cases showed diffuse mesothelin expression 
with 5B2 and MN-1 immunostaining, respectively. 
Epithelioid mesothelioma showed significantly higher 
mesothelin expression (81% with 5B2 and 84% with 
MN-1) than sarcomatoid (20% with 5B2 and 20% with 
MN-1) and biphasic (65% with 5B2 and 65% with MN-1) 
histotypes with both antibodies.
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 In adenocarcinoma of the lung, 5B2 showed slightly 
higher positivity (47%) than MN-1 (41%).
Adenocarcinoma of the prostate and lobular 
carcinoma of the breast were usually negative but 
occasionally showed cytoplasmic mesothelin-positivity 
(1–5% of cases).
Forty-one percent of thymic carcinomas were 
positive for mesothelin on the cell membrane with MN-1 
antibody. 5B2 showed dominant cytoplasmic staining 
in these tumors (Figure 5A). On the other hand, benign 
thymomas showed no positivity with either antibody 
(Figure 5B).
Squamous cell carcinoma of the lung (28% with 
5B2, 15% with MN-1) and uterine cervix (14% with 5B2, 
14% with MN-1) showed lower positivity than thymic 
carcinoma in this study.
Urothelial carcinomas and clear cell renal cell 
carcinomas showed rare positivity for mesothelin with 
both antibodies (4–13%, Figure 6A and 6B). In urothelial 
carcinoma, positive signals were especially detected in 
components with squamous cell differentiation (Figure 6A).
Survival analysis of mesothelioma patients
 Characteristics of the 66 mesothelioma patients 
analyzed for survival have been summarized in Table 3. 
Patients were followed up for up to 120 months. Survival 
was significantly longer for patients with mesothelioma 
expressing mesothelin diffusely (100% of positive 
cells) on the cell membrane using 5B2 (36.0 months 
median vs. 10.0 months with heterogeneous or no 
mesothelin expression; P = 0.002, Figure 7A) or MN-1 
(33.0 months median vs. 9.0 months with heterogeneous 
or no mesothelin expression; P < 0.001, Figure 7B) 
antibodies. Multivariable Cox hazards regression analysis 
revealed diffuse membranous mesothelin expression in 
mesothelioma tumor cells to be a favorable prognostic 
factor (HR, 0.36; 95% CI, 0.21–0.64; P < 0.001) (Table 4).
Table 1: Mesothelin expression in different types of tumors detected by clone 5B2, MN-1, MPF44 
and MPF25 antibodies
Figure 1: Mesothelin expression in malignant mesothelioma. (A) MN-1 antibody showed strong signal on the cell membrane. 
(B) MPF44 antibody showed cytoplasm-dominant staining.
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Correlation with mismatch repair system 
deficiency in gastrointestinal adenocarcinomas
 In gastrointestinal adenocarcinomas, 16% (29/183) 
of colorectal and 12% (9/77) of gastric adenocarcinomas 
showed mismatch repair (MMR)-deficient phenotypes. 
No significant correlation was detected between MMR-
deficiency and mesothelin-expression in gastric (P = 0.08) 
and colorectal (P = 0.51) adenocarcinomas (Supplementary 
Tables 1 and 2).
Table 2: Mesothelin expression in different types of tumors detected by clone 5B2 and MN-1 
antibodies
Diagnosis Total Mesothelin (5B2) Mesothelin (MN-1)
No. Luminal/membrane Total* Luminal/membrane Total*
No. % Range (median) No. %
Range 
(median) No. %
Range 
(median) No. %
Range 
(median)
Tumors with 
adenocarcinoma-like 
differentiation
Ovary, serous 
carcinoma 79 71 89.9 5–100 (90) 73 92.4 5–100 (90) 74 93.7 5–100 (100) 75 94.9 5–100 (100)
Pancreas, invasive 
ductal carcinoma 132 93 70.5 5–100 (50) 100 75.8 5–100 (80) 115 87.1 5–100 (80) 119 90.2 10–100 (100)
Uterus, endometrioid 
adenocarcinoma 82 52 63.4 5–100 (20) 62 75.6 5–100 (30) 51 62.2 5–100 (30) 59 72.0 5–100 (30)
Colorectum, 
adenocarcinoma 188 91 48.4 5–100 (10) 108 57.4 5–100 (30) 115 61.2 5–100 (30) 128 68.1 5–100 (45)
Lung, adenocarcinoma 76 36 47.4 5–100 (30) 50 65.8 5–100 (80) 31 40.8 5–100 (60) 47 61.8 5–100 (100)
Liver, 
cholangiocellular 
carcinoma
39 16 41.0 10–100 (60) 16 41.0 20–100 (95) 16 41.0 10–90 (80) 16 41.0 30–100 (100)
Stomach, 
adenocarcinoma 81 31 38.3 5–90 (20) 60 74.1 5–100 (80) 40 49.4 5–100 (20) 63 77.8 5–100 (90)
Mammary gland, 
invasive ductal 
carcinoma
119 13 10.9 5–60 (10) 13 10.9 5–100 (60) 14 11.8 5–80 (20) 16 13.4 5–100 (75)
Prostate gland, 
adenocarcinoma 107 0 0.0 - 1 0.9 90 (-) 0 0.0 - 1 0.9 90 (–)
Mammary gland, 
lobular carcinoma 82 0 0.0 - 0 0.0 - 0 0.0 - 4 4.9 5–100 (70)
Tumors with squamous cell 
differentiation
Thymic carcinoma 17 6 35.3 5–100 (93) 13 76.5 10–100 (100) 7 41.2 5–100 (90) 10 58.8 10–100 (95)
Lung, squamous cell 
carcinoma 72 20 27.8 5–90 (10) 33 45.8 5–100 (20) 11 15.2 5–100 (20) 20 27.8 5–100 (20)
Uterine cervix, 
squamous cell 
carcinoma
21 3 14.3 20–40 (20) 6 28.6 20–100 (90) 3 14.3 20–40 (20) 6 28.6 20–100 (90)
Thymoma 33 0 0.0 - 0 0.0 - 0 0.0 - 0 0.0 -
Other epithelial tumors
Malignant 
mesothelioma 143 107 75.0 5–100 (90) 111 77.6 5–100 (100) 111 77.6 5–100 (100) 113 79.0 10–100 (100)
 Epithelioid 115 93 80.9 5–100 (90) 97 84.3 5–100 (100) 97 84.3 5–100 (100) 99 86.1 10–100 (100)
 Biphasic 17 11 64.7 20–100 (70) 11 64.7 20–100 (100) 11 64.7 30–100 (80) 11 64.7 30–100 (100)
 Sarcomatoid 10 2 20.0 80 (80) 2 20.0 90–100 (95) 2 20.0 40–80 (60) 2 20.0 90–100 (95)
Urinary tract, 
urothelial carcinoma 85 11 12.9 5–100 (20) 18 21.2 10–100 (35) 7 8.2 5–100 (40) 14 16.5 5–100 (40)
Kidney, clear cell 
renal cell carcinoma 206 9 4.4 5–100 (20) 15 7.3 5–100 (50) 17 8.3 5–100 (20) 24 11.7 5–100 (30)
*total indicates mesothelin expression on luminal/membrane and/or cytoplasm.
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Correlation with gene mutation status in 
colorectal adenocarcinomas
 Arbitrary selected 75 colorectal tumors were 
analyzed for BRAF, KRAS, and NRAS gene mutations. 
Among them, 20 tumors showed BRAF V600E mutation 
and 30 tumors carried a mutated KRAS gene. Only one 
case showed mutation in the NRAS gene. All of the 
gene mutations were detected in a mutually exclusive 
manner. No statistical correlation was detected between 
Figure 2: Mesothelin expression in normal tissues. (A and B) MN-1 antibodies showed limited signal in the epithelium of fallopian 
tubes (A) and seminal vesicles (B). (C and D) Hassall’s corpuscles of the thymus (C) and a subset of squamous epithelial cells of the tonsils 
(D) showed mesothelin expression.
Table 3: Characteristics of the 66 mesothelioma patients analyzed for survival
Characteristics
Age, year
Mean 60.9 ± 10.5
Median (range) 61 (27–87)
Sex, no. (%)
Male 50 (76)
Female 16 (24)
Histology, no. (%)
Epithelial 56 (85)
Biphasic 7 (11)
Sarcomatoid 3 (5)
Tumor with diffuse membranous mesotheline (MN-1), no. (%)
33 (50)
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mesothelin expression and gene mutation status (P = 0.82, 
Supplementary Table 3).
DICUSSION
Mesothelin (MSLN) is a cell surface protein highly 
expressed in several types of malignant tumors, such 
as malignant mesothelioma, ovarian cancer, pancreatic 
adenocarcinoma, and lung adenocarcinoma, sometimes 
in association with increased tumor aggressiveness and 
poor clinical outcome. Several antibody-based therapeutic 
agents, vaccines, and T cell therapies against mesothelin, 
in some case, have shown favorable results [17]. Serum 
mesothelin levels have been found to correlate with 
mesothelioma responsiveness to anti-mesothelin therapies 
[12, 13, 18, 19]. However, the clinical usefulness of 
mesothelin immunohistochemistry, including for the 
prognostication of malignant pleural mesothelioma 
patients, has not been fully examined [3–10].
In the present study, mesothelin expression 
was evaluated using five different mouse monoclonal 
antibodies against mesothelin (clone 5B2 and MN-1) 
and MPF (megakaryocyte potentiating factor)/precursor 
mesothelin (MPF25, MPF44 and MPF49), in order to 
determine the optimal antibodies for mesothelin detection 
in common carcinomas. Since the anti-mesothelin (5B2 
and MN-1) antibodies offered a superior signal quality 
in a preliminary study, they were used to analyze 1562 
tumors to compare immunoreactivities of selected tumors 
as well as to test their clinical utility for pathological 
diagnosis and prognostication of mesothelioma patients. 
Furthermore, immunohistochemistry (MLH1, MSH2, 
MSH6, and PMS2) and gene mutation analyses (BRAF, 
KRAS, and NRAS) were performed to characterize the 
mesothelin-positive tumors. 
Almost all ovarian serous carcinomas showed 
high-levels of mesothelin expression with both 5B2 and 
MN-1 anti-mesothelin antibodies. In the present study, 
these antibodies also showed similar high positivity (up 
to 70–80% of cases) in malignant mesothelioma and 
uterine endometrioid adenocarcinoma. Patients with these 
mesothelin-positive tumors are potential candidates for the 
Figure 3: Mesothelin expression in ovary serous carcinoma. (A and B) Both 5B2 (A) and MN-1 (B) antibodies showed strong 
signal on the apical side of the cell membrane.
Figure 4: Mesothelin expression in adenocarcinoma of the pancreas. (A and B) MN-1 (A) showed higher positivity than 5B2 
(B) antibody.
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mesothelin-targeting therapeutics such as a recombinant 
immunotoxin (SS1P), a high-affinity chimeric monoclonal 
antibody (MORAb-009), an anti-mesothelin antibody 
drug conjugate (BAY 94-9343), or adoptive T-cell 
immunotherapy using mesothelin-specific chimeric antigen 
receptors (CAR) in autologous T-lymphocytes [15].
Up to 80% of thymic carcinomas showed 
homogeneous and strong cell membrane and/or cytoplasmic 
staining for mesothelin. On the other hand, thymomas showed 
no positivity for mesothelin immunostaining with either 
antibody. Therefore, mesothelin immunohistochemistry with 
either antibody could have a role in differentiating thymic 
carcinomas from thymomas.
In adenocarcinomas arising in the pancreas, 
stomach, and colorectum, MN-1 antibodies showed a 
more prominent mesothelin positivity rate than 5B2. On 
the other hand, squamous cell carcinoma of the lung and 
urothelial carcinoma of the urinary tract, 5B2 showed 
slightly higher positivity.
In ELISA and immunoblot assay, MN-1 antibody 
showed much higher affinity than 5B2 antibody. 
Furthermore, 5B2 antibody showed lower or no affinity 
to native mesothelin expressed in human cells [22]. 
However, appropriate antigen retrieval and dilution of the 
antibodies led to favorable immunohistochemical staining 
results with 5B2 antibody [22]. It is likely that the different 
staining patterns and rates of positivity obtained with 5B2 
and MN-1 antibodies are due to the differential expression 
of the various mesothelin epitopes in these tumors. 
Furthermore, these results suggest that appropriate type of 
anti-mesothelin antibody should be used when evaluating 
mesothelin expression in different tumor types. A thorough 
Figure 5: Mesothelin immunostaining with 5B2 in thymic tumors. (A and B) thymic carcinoma (A) showed diffuse cytoplasm-
dominant staining, however, thymoma (B) showed no signal.
Figure 6: Mesothelin immunostaining with 5B2 in urothelial and clear cell renal cell carcinoma. (A and B) urothelial 
carcinoma (A) showed positive staining on the site of squamous metaplastic differentiation. Clear cell renal cell carcinoma (B) showed 
positive signal on the cell membrane.
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analysis of mesothelin expression in tumors being targeted 
by anti-mesothelin agents will be important to understand 
the correlation between mesothelin expression and 
treatment response.
Among the MPF antibodies, MPF44 has been shown 
to react with the full-length mesothelin precursor protein, 
a 71 kDa protein without cleavage, and the shed 31 kDa 
MPF, in immunoblot analyses [23]. These results indicate 
that mesothelin precursor protein might also be detected in 
immunohistochemistry by MPF25 and MPF 44 antibodies, 
however, soluble factor MPF may be harder to detect in 
formalin-fixed paraffin-embedded (FFPE) tissue sections. 
Our results suggest that malignant mesotheliomas express 
processed mesothelin on the cell membrane because 5B2 
and MN-1 typically showed membrane positivity, whereas 
MPF44 showed predominantly cytoplasmic staining. We 
also show that MPF49 does not react with MPF protein 
in immunoblot analysis under SDS-denatured conditions 
probably indicating reactivity with a conformation-
sensitive epitope [23]. This might also explain why MPF49 
showed no specific staining in FFPE sections in this study.
In the present study, different from other types of 
tumors such as adenocarcinoma of the lung and stomach, 
mesothelin expression itself did not show any impact on 
the survival of the mesothelioma patients (data not shown) 
[8–10]. However, patients with malignant mesothelioma 
expressing mesothelin diffusely (100% of positive cells 
on the cell membrane) had increased overall survival 
compared to patients whose tumors had heterogeneous or 
no mesothelin expression. Since we did not have detailed 
clinical information about other patient characteristics 
such as clinical stage of their disease or performance 
status it is difficult to say whether diffuse mesothelin 
expression by itself is an independent favorable prognostic 
factor. This will need to be validated in larger studies with 
defined patient characteristics.
Several types of lung carcinomas have been reported 
to express mesothelin [6]. In case of lung adenocarcinoma 
high-level of mesothelin expression is associated with 
aggressiveness, poor prognosis and KRAS gene mutation 
status [8, 9]. Based on these observations, in the present 
study, gene mutation analyses were performed in 
colorectal adenocarcinomas since they commonly harbor 
KRAS mutations. Among 75 arbitrarily selected colorectal 
adenocarcinomas, 20 and 31 tumors carried BRAF and 
RAS mutations, respectively. However, no significant 
correlation between mesothelin-expression and gene 
mutation status was detected. These results indicate 
different relationship between mesothelin expression and 
gene mutations in colorectal and lung adenocarcinomas.
In normal tissues, mesothelin expression was detected 
in the mesothelial cells, epithelium of the fallopian tubes 
and seminal vesicles. Also, focal expression was seen in 
Hassall’s corpuscles of the thymus and a subset of squamous 
epithelial cells of the tonsils. The biologic function of 
mesothelin is not well known including in these tissues. 
In conclusion, many tumors such as mesothelioma 
and ovarian serous carcinoma showed equal 
immunoreactivity with both 5B2 and MN-1 antibodies, 
however, differences in mesothelin expression were seen 
in other tumor types using 5B2 or MN-1 antibodies. 
This has to be taken into account when selecting patients 
for anti-mesothelin immunotherapies. Mesothelin 
immunohistochemistry may also assist in the differential 
diagnosis of thymoma versus thymic carcinoma. 
Furthermore, mesothelin immunohistochemistry could 
be useful for the prognostication of malignant pleural 
mesothelioma patients.
Figure 7: Overall survival of malignant pleural mesothelioma cases classified with mesothelin expression. (A and B) 
Kaplan-Meier curves for the patients carrying mesothelioma grouped with diffuse membranous or partial/negative mesothelin expression 
stained with 5B2 (A) and MN-1 (B) antibodies.
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MATERIALS AND METHODS
Tissue samples
This project was completed under Office of Human 
Subject Research Exemption with anonymized specimens. 
For the analysis of physiological expression, a panel of 
normal tissues was evaluated for mesothelin expression. 
For neoplastic conditions, 1562 of extensively characterized 
tumors were subjected to immunohistochemical analyses. 
Tumor samples derived from surgical specimens were 
assembled into multitumor blocks containing up to 60 
rectangular tissue samples as previously described [24]. 
The size of tumor sample was estimated to exceed the size 
of a single 0.6mm2 core by a factor of 10–15.
Antibodies and cells
The information of the antibodies has been 
summarized in Table 5. It was noted that 5B2 was generated 
by immunizing mice with a recombinant prokaryotic 
fusion protein corresponding to 100 amino acids which is 
also present in the N terminal Region I of mesothelin by 
the company (Novocastra/Leica, Bannockburn, IL). On the 
other hand, MN-1 was generated in mesothelin-deficient 
mice by immunization with plasmid cDNA corresponding 
to the mesothelin extracellular domain followed by a single 
boost with a recombinant human mesothelin-Fc fusion 
protein [22]. The validity of 5B2 and MN-1 antibodies was 
confirmed by immunoblot analyses using malignant pleural 
mesothelioma and pancreatic cancer cells. (Supplementary 
Figure 1) PANC-1 and SUIT-2 human pancreatic ductal 
adenocarcinoma cell lines were obtained from the RIKEN 
BioResource Center (Tsukuba, Japan). The human 
malignant pleural mesothelioma cell lines, ACC-MESO-4 
and Y-MESO-8A, were kindly provided by Dr. Yoshitaka 
Sekido (Aichi Cancer Center Research Institute) [25].
Immunohistochemistry
Immunohistochemistry was performed using the 
Leica Bond-Max automation and Leica Refine detection kit 
(Leica Biosystems, Bannockburn, IL). The conditions for 
immunostaining have been summarized in Table 5. Signals 
were visualized by DAB. Mesothelin immunoreactivity 
(luminal/membranous or cytoplasmic) was evaluated with 
a detection cut-off of 5%. To compare the mesothelin 
positivity in small rectangular tissue samples on the 
tissue array and the corresponding larger whole-slide 
donor samples, 31 cases were selected for comparative 
immunohistochemical analysis.  The results showing a high 
concordance are illustrated in Supplementary Figure 2. 
Immunohistochemistry of MLH1, MSH2, MSH6, and 
PMS2 were performed as previously reported [26, 27].
Sequencing analysis
In colorectal tumors, arbitrary selected 75 samples 
were subjected to sequencing analysis in BRAF, KRAS, 
and NRAS genes. Mutation analyses were done by PCR 
and Sanger sequencing as previously reported [26]. Primer 
sequences, PCR conditions and size of amplicons are 
provided in Supplementary Table 4.
Statistical analysis
All statistical analyses were performed with EZR 
version 1.32. software [28]. Chi-square or Fisher’s exact 
test were performed to investigate the statistical correlation. 
To analyze the impact of the mesothelin expression on 
overall survival of mesothelioma patients, Kaplan-Meier 
survival estimates with log-rank test was performed. Cox 
proportional hazards regression analysis was used to 
analyze the association of survival and other factors. The 
initial model included age (< 65 vs. ≧ 65 years old), sex 
(male vs. female), tumor histology (epithelial vs. biphasic 
vs. sarcomatoid) and data from immunohistochemistry 
(diffuse mesothelin expression: 100% of positive cells 
on the cell membrane vs. negative or partial mesothelin 
expression in any location) for mesothelin with MN-1 and 
5B2 antibody. A backward elimination with a threshold of 
P = 0.05 was used to select variables in the final model. 
Cases with missing information were eliminated from the 
statistical analysis of that parameter.
Table 4: Cox hazard ratio of malignant pleural mesothelioma patients
Hazard 95% CI
Ratio min max P-value
Membranous mesothelin expression 
(MN-1)
Partial or negative 1
Diffuse (100% of positive cells on the 
cell membrane) 0.36 0.21 0.64 < 0.001 *
The multivariable Cox hazards analysis model initially included age, sex, tumor histology, and mesothelin expression (MN-1 
antibody).
A backward elimination with a threshold of P = 0.05 was used to select variables in the final model.
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